Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153869 | 0.90 | CRBN (0.60) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20133101 | 0.86 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22737163 | 0.85 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24185741 | 0.85 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23138921 | 0.85 | CRBN (0.47) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24758806 | 0.83 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24746613 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29547940 | 0.82 | CRBN (0.50) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22906842 | 0.82 | CRBN (0.50) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20153862 | 0.82 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023097020-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| WO-2021113557-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 750/4885ALDH1A1 798/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 746/4885ALDH1A1 824/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885DDB1 746/4885ALDH1A1 824/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885DDB1 418/4885ALDH1A1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.